TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned an average rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $6.00.

Several equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd. Wedbush raised their price objective on TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Thursday, March 5th. Finally, Wall Street Zen downgraded TScan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.

TScan Therapeutics Stock Performance

TScan Therapeutics stock opened at $1.05 on Monday. TScan Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $2.57. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.41 and a current ratio of 8.41. The stock has a market cap of $59.59 million, a P/E ratio of -1.05 and a beta of 1.03. The firm’s fifty day moving average price is $1.08 and its 200-day moving average price is $1.36.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.09. The company had revenue of $2.57 million during the quarter, compared to analyst estimates of $2.44 million. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 79.36%. On average, equities research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Activity at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were purchased at an average cost of $0.90 per share, with a total value of $72,062.10. Following the completion of the purchase, the insider owned 7,937,416 shares of the company’s stock, valued at $7,143,674.40. The trade was a 1.02% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have purchased 161,801 shares of company stock worth $145,621 over the last quarter. Company insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Boothbay Fund Management LLC grew its holdings in shares of TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after purchasing an additional 9,676 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in TScan Therapeutics in the second quarter worth $26,000. Letko Brosseau & Associates Inc. boosted its position in TScan Therapeutics by 24.4% during the second quarter. Letko Brosseau & Associates Inc. now owns 95,875 shares of the company’s stock valued at $139,000 after buying an additional 18,775 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in TScan Therapeutics during the second quarter valued at about $33,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.